BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024.

MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT. The event brings together professionals, fostering valuable networking opportunities with industry peers, potential partners, and customers from around the globe. It serves as a comprehensive platform for growth, learning, and collaboration within the healthcare sector.

Sonoma Pharmaceuticals is aiming to expand its distributor network and is eager to showcase its products and technologies to a global audience, forging valuable connections with potential partners and industry customers. Interested parties are invited to visit Sonoma Pharmaceuticals' booth (F12-5) in Hall 15 to learn about its patented, innovative, safe, and effective products for the treatment of scar management, atopic dermatitis, and acne, as well as wound care and eyelid infection. For more information, please visit https://sonomapharma.com.

"We are excited to present our portfolio of products at MEDICA, an event celebrated for bringing together thousands of attendees and visitors, including key decision-makers from across the globe. This distinguished platform offers a unique opportunity for us to introduce potential new partners to Sonoma's products, which are supported by our innovative Microcyn technology. MEDICA serves as an exceptional venue for fostering significant collaborations that will be essential in shaping the future direction of enhanced healthcare outcomes," stated Amy Trombly, CEO of Sonoma Pharmaceuticals.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn ^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Website: www.sonomapharma.com

Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals

Follow us on Instagram: https://www.instagram.com/sonomapharma_us/

Follow us on Facebook: https://www.facebook.com/sonomapharma/